Gibbs Terrence Michael's most recent trade in T2 Biosystems Inc was a trade of 190,000 Restricted Stock Units done . Disclosure was reported to the exchange on Nov. 4, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 190,000 | 190,000 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Gibbs Michael Terrence | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Nov 2024 | 190,000 | 190,000 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Terrence Michael Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2024 | 29 | 0 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Terrence Michael Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2024 | 29 | 135 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Gibbs Terrence Michael | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 40 | 40 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 40 | 106 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Sale of securities on an exchange or to another person at price $ 0.48 per share. | 28 Mar 2023 | 239 | 6,612 (0%) | 0% | 0.5 | 115 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2023 | 334 | 0 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2023 | 334 | 6,851 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 4,000 | 8,000 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 4,000 | 7,333 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 2,914 | 8,102 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2023 | 2,914 | 2,914 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Sale of securities on an exchange or to another person at price $ 0.65 per share. | 20 Feb 2023 | 2,145 | 5,188 (0%) | 0% | 0.6 | 1,394 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 20 Feb 2023 | 1,585 | 6,517 (0%) | 0% | 0.6 | 935 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Purchase of securities on an exchange or from another person at price $ 0.49 per share. | 07 Apr 2022 | 10,000 | 166,651 (0%) | 0% | 0.5 | 4,900 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2022 | 16,666 | 16,667 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2022 | 16,666 | 165,441 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.44 per share. | 24 Mar 2022 | 8,790 | 156,651 (0%) | 0% | 0.4 | 3,876 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2022 | 145,719 | 291,439 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2022 | 145,719 | 225,642 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.45 per share. | 24 Feb 2022 | 76,867 | 148,775 (0%) | 0% | 0.4 | 34,498 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2022 | 600,000 | 600,000 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2022 | 10,000 | 0 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2022 | 10,000 | 85,198 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.47 per share. | 20 Feb 2022 | 5,275 | 79,923 (0%) | 0% | 0.5 | 2,458 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2021 | 16,667 | 33,333 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Mar 2021 | 16,667 | 82,014 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Sale of securities on an exchange or to another person at price $ 1.56 per share. | 24 Mar 2021 | 8,758 | 73,256 (0%) | 0% | 1.6 | 13,662 | Common Stock |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Feb 2021 | 437,158 | 437,158 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 10,000 | 72,627 (0%) | 0% | - | Common Stock | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2021 | 10,000 | 10,000 | - | - | Restricted Stock Units | |
T2 Biosystems Inc | Michael Terrence Gibbs | General Counsel | Sale of securities on an exchange or to another person at price $ 2.06 per share. | 21 Feb 2021 | 7,280 | 65,347 (0%) | 0% | 2.1 | 14,997 | Common Stock |